Skip to content
Oncology Research Hub

Nashville, Tennessee

Cancer clinical trials in Nashville, TN

344 cancer studies are recruiting participants at sites in Nashville as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Nashville at a glance

  • 344 studies are recruiting at a site in Nashville.
  • By phase: Early Phase 1 (1), Phase 1 (90), Phase 1/2 (83), Phase 2 (60), Phase 2/3 (10), Phase 3 (76), Phase 4 (4), No phase (4), Observational (16). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (286), university, hospital or other (48), government (10).
  • By research area: Breast Cancer (116), Lung Cancer (100), Lymphoma (58), Prostate Cancer (32), Melanoma (20), Pancreatic Cancer (18).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Nashville

Basic details from each study's public record (the 30 most recently updated of 344). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study sites
    SCRI Oncology Partners · Tennessee Oncology, Pllc
    Registry record
    NCT06324357 · updated
  2. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Vanderbilt Breast Center at One Hundred Oaks
    Registry record
    NCT05422794 · updated
  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Vanderbilt Breast Center at One Hundred Oaks · Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT05564377 · updated
  4. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    Tennessee Oncology
    Registry record
    NCT06270706 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Nashville, TN on ClinicalTrials.gov.

Lung cancer studies recruiting in Nashville

  1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Sarah Cannon Research Institute
    Registry record
    NCT07277413 · updated
  2. A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eikon Therapeutics
    Study site
    Tennessee Oncology
    Registry record
    NCT07365319 · updated
  3. A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Tennessee Oncology, PLLC
    Registry record
    NCT07730021 · updated
  4. A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
    Registry record
    NCT07903415 · updated
  5. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
    Registry record
    NCT03460977 · updated
  6. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    • Phase 3
    • Ages 18 to 100
    • All sexes
    Sponsor
    Amgen
    Study site
    Sarah Cannon Research Institute
    Registry record
    NCT05920356 · updated
  7. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Sarah Cannon Research Institute-Nashville-48456
    Registry record
    NCT04886804 · updated
  8. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    Tennessee Oncology - Nashville Centennial Clinic
    Registry record
    NCT05099172 · updated
  9. Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    OSE Immunotherapeutics
    Study sites
    Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) - Corporate · Tennessee Oncology - Nashville - St. Thomas West Clinic
    Registry record
    NCT06472245 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Nashville, TN on ClinicalTrials.gov.

Prostate cancer studies recruiting in Nashville

  1. High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    VA Office of Research and Development
    Study site
    Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
    Registry record
    NCT05011383 · updated
  2. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SCRI Oncology Partners ( Site 7000)
    Registry record
    NCT06136624 · updated
  3. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Nashville, TN on ClinicalTrials.gov.

Melanoma studies recruiting in Nashville

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Nashville, TN on ClinicalTrials.gov.

Lymphoma studies recruiting in Nashville

  1. Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Tennessee Oncology
    Registry record
    NCT06806033 · updated
  2. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07221500 · updated
  3. Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07520006 · updated
  4. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SCRI Oncology Partners ( Site 7000)
    Registry record
    NCT06717347 · updated
  5. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SCRI Oncology Partners ( Site 7002)
    Registry record
    NCT06890884 · updated
  6. A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Henry-Joyce Cancer Clinic ( Site 0115) · SCRI Oncology Partners ( Site 0100)
    Registry record
    NCT07519772 · updated
  7. A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SCRI Oncology Partners ( Site 7000)
    Registry record
    NCT07634471 · updated
  8. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT04546399 · updated
  9. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT05675410 · updated
  10. A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT06091254 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Nashville, TN on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Nashville

  1. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    • Phase 2
    • Ages 12 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Vanderbilt University Medical Center ( Site 0107)
    Registry record
    NCT04924075 · updated
  2. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study sites
    Investigative Site US039 · Investigative Site US060 · Investigative Site US070
    Registry record
    NCT07522073 · updated
  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Sarah Cannon Research Institute
    Registry record
    NCT07644559 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Nashville, TN on ClinicalTrials.gov.

Ask about studies near Nashville

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call